Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic

3022 - Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057


09 Oct 2016


NSCLC, metastatic


Martin Reck


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


M. Reck1, J.R. Brahmer2, B. Bennett3, F. Taylor4, J.R. Penrod5, M. Derosa4, H. Dastani5, R. Gralla6

Author affiliations

  • 1 Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), 22927 - Grosshansdorf/DE
  • 2 Department Of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore/US
  • 3 Patient-centered Outcomes, Adelphi Values Ltd, SK10 5JB - Bollington/GB
  • 4 Patient-centered Outcomes, Adelphi Values, Boston/US
  • 5 Global Health Economics And Outcomes Research, Bristol-Myers Squibb, Princeton/US
  • 6 Department Of Medicine (oncology), Albert Einstein College of Medicine, New York/US


Abstract 3022


The CheckMate 057 randomized, open-label, phase III study evaluated the efficacy and safety of nivo vs doc in previously-treated pts with adv NSQ NSCLC. Overall survival was significantly improved with nivo vs doc, as were symptoms as assessed by the Lung Cancer Symptom Scale. Here we report the impact of nivo vs doc on overall pt-reported HS.


The EuroQoL-5 Dimensions visual analog scale (EQ-5D VAS) and EQ-5D utility index (UI) (scaled 0 to 100 and −0.594 to +1, respectively) were assessed every other cycle (Q4W) for nivo and every cycle (Q3W) for doc for the first 6 mo on treatment (tx), then every 6 wks and at 2 post-tx follow-up visits. Changes from baseline (BL) at individual assessments (asmts), a mixed-effects model (MMRM) of change from BL over all on-tx asmts, and time to first deterioration (TTD) in HS were evaluated. The minimally important difference (MID) is ≥7 points for the EQ-5D VAS and ≥0.08 points for the UI.


At on-tx asmts with >10 pts (through wk 78), EQ-5D VAS briefly worsened from BL in nivo pts at wk 4 (MID) at wks 24 and 36. There were no statistically significant changes from BL at any on-tx asmt in EQ-5D VAS scores for doc pts or in EQ-5D UI scores for nivo (apart from a worsening [


The EQ-VAS results from this phase III study showed that nivo pts with previously-treated adv NSQ NSCLC had improvements in on-tx HS while doc pts' on-tx HS was stable. TTD in health status per the EQ-VAS was significantly longer in nivo- vs doc-treated pts.

Clinical trial identification


Legal entity responsible for the study

Bristol-Myers Squibb


Bristol-Myers Squibb


M. Reck: Speakers' Bureau and consulting/advisory role for Roche, Lilly, BMS, MSD, AZ, Pfizer, BI, Celgene. J.R. Brahmer: Consulting/Advisory role for Celgene, Lilly, Merck (BMS-uncompensated) and research funding from BMS, MedImmune/AZ, Merck. B. Bennett: Employment from AZ, research funding from Adelphi Values, and consulting/advisory role with Adelphi Values. F. Taylor: Research funding and Consulting or advisory role from Adelphi Values, a consultancy paid by BMS to analyze BMS clinical trial data. J.R. Penrod: Employment and stock options: BMS. H. Dastani: Employment and Stock or Other Ownership from BMS. R. Gralla: Honoraria from Merck and consulting/advisory role with BMS, Merck, Lilly, BI. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings